OBJECTIVE: The purpose of this study was to determine the short-term and midterm outcomes of catheter-directed intervention (CDI) compared with anticoagulation (AC) alone in patients with submassive pulmonary embolism (sPE). METHODS: This was a retrospective review of all patients treated for sPE between January 2009 and October 2014. Two groups were identified on the basis of the therapy: AC and CDI. End points included complications, mortality, and change in echocardiographic parameters. Standard statistical techniques were used. RESULTS: There were 64 patients who received AC and 64 patients who received CDI (five were initially treated with AC but did not improve or worsened; six received ≤8 mg of tissue plasminogen activator). Most baseline characteristics, including the Pulmonary Embolism Severity Index, were similar among the AC and CDI groups. There was no difference in PE-related death (one in each group) or major bleeding events (three in the AC group, four in the CDI group), but CDIs had two additional procedural complications that required open heart surgery. CDIs showed significantly more minor bleeding events (6 vs 0; P = .028) and significantly shorter intensive care unit stay (2.7 ± 2.1 vs 5.6 ± 7.5 days; P = .04). The mean difference in right ventricular/left ventricular ratio from baseline to the first subsequent echocardiogram (within 30 days) showed a trend for higher reduction in favor of CDI (AC, 0.17 ± 0.12; CDI, 0.27 ± 0.15; P = .076). Between 3 and 8 months, significant improvement was evident within groups in all assessed right-sided heart echocardiographic parameters, but there was no difference between groups. Pulmonary hypertension (pulmonary artery pressure >40 mm Hg) was present in 7 of 15 of the AC group vs 6 of 19 of the CDI group (P = .484). During the follow-up, dyspnea or oxygen dependence, not existing before the index PE event, was recorded in 5 of 49 (10.2%) of the AC patients and 8 of 52 (15.4%) of the CDI patients (P = .556). CONCLUSIONS: CDI for sPE can result in faster restoration of right ventricular function and shorter intensive care unit stay, but at the cost of a higher complication rate, with similar midterm outcomes compared with AC alone. A potential effect of CDI on mortality and pulmonary hypertension needs further investigation through larger studies.
OBJECTIVE: The purpose of this study was to determine the short-term and midterm outcomes of catheter-directed intervention (CDI) compared with anticoagulation (AC) alone in patients with submassive pulmonary embolism (sPE). METHODS: This was a retrospective review of all patients treated for sPE between January 2009 and October 2014. Two groups were identified on the basis of the therapy: AC and CDI. End points included complications, mortality, and change in echocardiographic parameters. Standard statistical techniques were used. RESULTS: There were 64 patients who received AC and 64 patients who received CDI (five were initially treated with AC but did not improve or worsened; six received ≤8 mg of tissue plasminogen activator). Most baseline characteristics, including the Pulmonary Embolism Severity Index, were similar among the AC and CDI groups. There was no difference in PE-related death (one in each group) or major bleeding events (three in the AC group, four in the CDI group), but CDIs had two additional procedural complications that required open heart surgery. CDIs showed significantly more minor bleeding events (6 vs 0; P = .028) and significantly shorter intensive care unit stay (2.7 ± 2.1 vs 5.6 ± 7.5 days; P = .04). The mean difference in right ventricular/left ventricular ratio from baseline to the first subsequent echocardiogram (within 30 days) showed a trend for higher reduction in favor of CDI (AC, 0.17 ± 0.12; CDI, 0.27 ± 0.15; P = .076). Between 3 and 8 months, significant improvement was evident within groups in all assessed right-sided heart echocardiographic parameters, but there was no difference between groups. Pulmonary hypertension (pulmonary artery pressure >40 mm Hg) was present in 7 of 15 of the AC group vs 6 of 19 of the CDI group (P = .484). During the follow-up, dyspnea or oxygen dependence, not existing before the index PE event, was recorded in 5 of 49 (10.2%) of the ACpatients and 8 of 52 (15.4%) of the CDIpatients (P = .556). CONCLUSIONS:CDI for sPE can result in faster restoration of right ventricular function and shorter intensive care unit stay, but at the cost of a higher complication rate, with similar midterm outcomes compared with AC alone. A potential effect of CDI on mortality and pulmonary hypertension needs further investigation through larger studies.
Authors: Gregory Piazza; Benjamin Hohlfelder; Michael R Jaff; Kenneth Ouriel; Tod C Engelhardt; Keith M Sterling; Noah J Jones; John C Gurley; Rohit Bhatheja; Robert J Kennedy; Nilesh Goswami; Kannan Natarajan; John Rundback; Immad R Sadiq; Stephen K Liu; Narinder Bhalla; M Laiq Raja; Barry S Weinstock; Jacob Cynamon; Fakhir F Elmasri; Mark J Garcia; Mark Kumar; Juan Ayerdi; Peter Soukas; William Kuo; Ping-Yu Liu; Samuel Z Goldhaber Journal: JACC Cardiovasc Interv Date: 2015-08-24 Impact factor: 11.195
Authors: Michael R Jaff; M Sean McMurtry; Stephen L Archer; Mary Cushman; Neil Goldenberg; Samuel Z Goldhaber; J Stephen Jenkins; Jeffrey A Kline; Andrew D Michaels; Patricia Thistlethwaite; Suresh Vedantham; R James White; Brenda K Zierler Journal: Circulation Date: 2011-03-21 Impact factor: 29.690
Authors: James M McCabe; Pei-Hsiu Huang; Lauren Riedl; Andrew C Eisenhauer; Piotr Sobieszczyk Journal: Am J Cardiol Date: 2015-01-07 Impact factor: 2.778
Authors: Guy Meyer; Eric Vicaut; Thierry Danays; Giancarlo Agnelli; Cecilia Becattini; Jan Beyer-Westendorf; Erich Bluhmki; Helene Bouvaist; Benjamin Brenner; Francis Couturaud; Claudia Dellas; Klaus Empen; Ana Franca; Nazzareno Galiè; Annette Geibel; Samuel Z Goldhaber; David Jimenez; Matija Kozak; Christian Kupatt; Nils Kucher; Irene M Lang; Mareike Lankeit; Nicolas Meneveau; Gerard Pacouret; Massimiliano Palazzini; Antoniu Petris; Piotr Pruszczyk; Matteo Rugolotto; Aldo Salvi; Sebastian Schellong; Mustapha Sebbane; Bozena Sobkowicz; Branislav S Stefanovic; Holger Thiele; Adam Torbicki; Franck Verschuren; Stavros V Konstantinides Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245
Authors: J A Kline; K E Nordenholz; D M Courtney; C Kabrhel; A E Jones; M T Rondina; D B Diercks; J R Klinger; J Hernandez Journal: J Thromb Haemost Date: 2014-04 Impact factor: 5.824
Authors: Bennet George; Eric L Wallace; Richard Charnigo; Kelly E Wingerter; Pavan Kapadia; John C Gurley; Susan S Smyth Journal: Vasc Med Date: 2015-04 Impact factor: 3.239
Authors: Silvy Laporte; Patrick Mismetti; Hervé Décousus; Fernando Uresandi; Remedios Otero; Jose Luis Lobo; Manuel Monreal Journal: Circulation Date: 2008-03-17 Impact factor: 29.690
Authors: Drahomir Aujesky; David Jiménez; Maria K Mor; Ming Geng; Michael J Fine; Said A Ibrahim Journal: Circulation Date: 2009-02-09 Impact factor: 29.690
Authors: Efthymios D Avgerinos; Adham N Abou Ali; Nathan L Liang; Belinda Rivera-Lebron; Catalin Toma; Robert Maholic; Michel S Makaroun; Rabih A Chaer Journal: J Vasc Surg Venous Lymphat Disord Date: 2018-03-31
Authors: Andrew Putnam; Kyle Carey; Alexandru Marginean; Anthony Serritella; Janet Friant; John Blair; Atman Shah; Sandeep Nathan; Matthew Churpek; Jonathan Paul Journal: J Thromb Thrombolysis Date: 2021-05-25 Impact factor: 2.300